Management of patients refractory of platelet transfusion

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

Leukemia·2012

Investigations of peptide hydration using NMR and molecular dynamics simulations: A study of effects of water on the conformation and dynamics of antamanide.

Journal of biomolecular NMR·2010

Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

Leukemia·2003

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).

Leukemia·2003

Diagnosis and management of refractoriness to platelet transfusion.

Blood reviews·2002

Signal transduction inhibition: changing paradigms in cancer care.

Seminars in oncology·2001

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

Leukemia·2026

Cheminformatic identification of small molecules targeting acute myeloid leukemia.

Leukemia·2026

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Leukemia·2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Leukemia·2026

PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.

Leukemia·2026

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

Leukemia·2026

Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

Journal of clinical and experimental hematopathology : JCEH·2026

[Complement-coagulation crosstalk in immunothrombosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Hematological diseases caused by excessive complement activation].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Utility of global coagulation assays for hemostasis management in hyperclearance-type autoimmune acquired coagulation factor V deficiency].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Association of Pretreatment Hepatic Function Markers with Clazosentan-Associated Fluid Retention in Patients with Subarachnoid Hemorrhage.

Biological & pharmaceutical bulletin·2026

Related Experiment Videos

Management of patients refractory of platelet transfusion

Related Concept Videos

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

Investigations of peptide hydration using NMR and molecular dynamics simulations: A study of effects of water on the conformation and dynamics of antamanide.

Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).

Diagnosis and management of refractoriness to platelet transfusion.

Signal transduction inhibition: changing paradigms in cancer care.

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

Cheminformatic identification of small molecules targeting acute myeloid leukemia.

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

[Complement-coagulation crosstalk in immunothrombosis].

[Hematological diseases caused by excessive complement activation].

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

[Utility of global coagulation assays for hemostasis management in hyperclearance-type autoimmune acquired coagulation factor V deficiency].

Association of Pretreatment Hepatic Function Markers with Clazosentan-Associated Fluid Retention in Patients with Subarachnoid Hemorrhage.

Related Experiment Videos

Management of patients refractory of platelet transfusion

Related Concept Videos

Related Articles